The Therapeutic Goods
Administration has issued a
“monitoring communication”
relating to ivabradine (Coralan)
which is PBS listed for the
treatment of heart failure and
stable angina.
Preliminary results from the
SIGNIFY study into the drug have
shown a statistically significant
increase in the combined risk of
death and non-fatal heart attack,
with the TGA continuing to monitor
adverse event reports involving the
medication.
Servier Laboratories notified
the TGA of the emerging safety
issue, and has also written to
health professionals regarding the
importance of monitoring heart
rate in patients taking Coralan and
the need to avoid concomitant use
of calcium-channel blockers.
CLICK HERE for details.The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jun 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jun 14
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.